Clene Nanomedicine
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Utah, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
6550 S Millrock Dr Ste G50, Salt Lake Ci...Phone Number
(801) 676-9695Website
www.clene.comRevenue
<$5 MillionStock Symbol
CLNNIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Clene Nanomedicine
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectiousRead more
Clene Nanomedicine Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Clene Nanomedicine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Clene Nanomedicine
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Clene Nanomedicine recently announced quarterly report
Product Launch: Get notified when Clene Nanomedicine launches new products
Check if Clene Nanomedicine has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Clene Nanomedicine has new funding data
Click to see if Clene Nanomedicine had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Clene Nanomedicine is spiking on competitors!
Clene Nanomedicine, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Clene Nanomedicine
Compare insights from companies similar to Clene Nanomedicine, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Clene Nanomedicine is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Clene Nanomedicine is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Clene Nanomedicine.
Clene Nanomedicine financials insights
Gather financial insights about Clene Nanomedicine, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$31.6M
2016
Series B
$17M
2020
Debt
$350K
Series D
$42.5M
2023
Other Financing Round
$40M
2024
Other Financing Round
$7.3M
2025
Stock/Share Issuance
$1.5M
Clene Nanomedicine Tech Stack
A closer look at the technologies used by Clene Nanomedicine
Most Recent Scoops
Earnings
Earnings, Finance
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
, according to a mid-level source in accounting, has completed initiatives related to project accounting within the last twelve months.
Accounting, Financial Reporting, Finance
Project
, according to a mid-level source in accounting, has completed initiatives related to benefits within the last twelve months.
Accounting, Compensation & Benefits, Financial Reporting, Finance
Project
Accounting, Financial Reporting, Finance
Clene Nanomedicine News & Media
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
SALT LAKE CITY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced its second quarter 2026 financial results and provided recent updates on its CNM-Au8 programs.Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS
Clene (NASDAQ:CLNN) said it is preparing to submit a new drug application, or NDA, in early fourth quarter for CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis, following a series of meetings with the U.S. Food and Drug Administration. President and CEO Rob Etherington said the coClene to Present at The Canaccord 46th Annual Growth Conference
SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 46th Annual Growth Conference and host 1x1 investor meetings.Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
SALT LAKE CITY, May 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late-stage clinical biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its first quarter 2026 financial results and provided recent updates on its CNM-Au8 programs.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Clene Nanomedicine
Sign Up For FreeTo access detailed company insights
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au... Read More
